Wave Life Sciences Ltd. Ordinary Shares - WVE STOCK NEWS

Wave Life Sciences highlighted its advanced candidate, WVE-006, for treating alpha-1 antitrypsin deficiency (AATD) during a recent virtual event. The RNA editing program aims to correct genetic mutations and restore functional protein levels. Preclinical data show a significant increase in AAT protein production and functional activity. Clinical trial applications for WVE-006 are expected to be submitted in 2023. Wave is also exploring broader applications for its AIMers technology beyond AATD, potentially impacting multiple diseases.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company, announced that CEO Paul Bolno will participate in an analyst-led fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, at 3:15 p.m. ET in New York City. A live webcast of the event will be accessible on the company's Investor Relations page, with a replay available for a limited time afterward. Wave Life Sciences focuses on developing innovative treatments for genetically defined diseases through its proprietary PRISM platform.

Wave Life Sciences Ltd. announces positive results from the SELECT-HD Phase 1b/2a clinical trial of WVE-003, a candidate for treating Huntington’s disease. Single doses of 30 or 60 mg led to a mean reduction of 22% in mutant huntingtin protein levels in cerebrospinal fluid, with a median reduction of 30%. The treatment was reportedly well-tolerated, with no serious adverse events. Wave plans to expand the dosing cohorts and has early data supporting allele-selective knockdown of the harmful protein. Further updates are expected in 1H 2023.

Wave Life Sciences (Nasdaq: WVE) announced an analyst and investor webcast on September 28, 2022, focusing on WVE-006, its first-in-class RNA editing candidate targeting alpha-1 antitrypsin deficiency (AATD). The event, titled 'Towards the Clinic: Spotlight on RNA Editing for AATD', will provide insights from AATD expert Dr. D. Kyle Hogarth and the Wave management team. WVE-006 aims to correct mutations in the SERPINA1 gene, addressing both lung and liver disease. Registration is available on Wave's website.

Wave Life Sciences (WVE) announced the selection of WVE-006 as its first RNA editing candidate for treating alpha-1 antitrypsin deficiency (AATD), with clinical trial applications expected in 2023. The company reported a net loss of $41.3 million for Q2 2022, down from $38.8 million a year earlier, with revenue declining to $0.4 million. Research and development expenses were $29.7 million, while general and administrative expenses increased to $12.8 million. A successful financing round in June 2022 raised $70 million, strengthening the balance sheet and providing cash runway until the end of 2023.

Wave Life Sciences (Nasdaq: WVE) will host a live webcast and conference call on August 11, 2022, at 8:30 a.m. ET to review its Q2 2022 financial results and provide a business update. Investors can access the webcast through the company's investor relations website. Analysts are encouraged to register in advance for the Q&A session. Wave Life Sciences focuses on developing genetic medicines for severe diseases, using its proprietary PRISM platform to create stereopure oligonucleotides.

Wave Life Sciences (Nasdaq: WVE) announced an underwritten offering of 25,464,483 ordinary shares at $2.15 each, representing a 7.5% premium over the June 13 closing price. Additionally, when issuing pre-funded warrants to buy 7,093,656 shares at $2.1499, they aim to raise approximately $70 million. The offering will close around June 16, 2022, subject to customary conditions. RA Capital Management is a notable participant, with SVB Securities acting as the bookrunning manager. The offering is made under a previously approved SEC registration statement.

Wave Life Sciences (Nasdaq: WVE) announced that its CEO, Paul Bolno, will participate in an analyst-led fireside chat at the 2022 Jefferies Healthcare Conference in New York City on June 8, 2022, at 3:00 p.m. ET. A live webcast will be available on Wave's Investor Relations page, with a replay accessible for a limited time after the event. Wave Life Sciences is focused on developing genetic medicines for serious diseases using its proprietary PRISM platform.

Wave Life Sciences (WVE) announced first clinical data from the FOCUS-C9 trial, showcasing effective target engagement of WVE-004 for C9-ALS and C9-FTD. The company reported a net loss of $37.8 million for Q1 2022, with revenues of $1.8 million, primarily from a collaboration with Takeda. R&D expenses decreased to $27.5 million, while G&A expenses rose to $12.4 million. Wave has $111.7 million in cash as of March 31, 2022, sufficient to fund operations into Q2 2023. Key clinical data updates are anticipated later this year for Huntington’s disease and Duchenne muscular dystrophy.